We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Lonza introduces Clonetics® Human Retinal Pigment Epithelial Cells and RtEGM™ Growth Medium

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Lonza announces the availability of cryopreserved Clonetics® Human Retinal Pigment Epithelial (hRPE) Cells and optimized RtEGM™ Growth Medium BulletKit® for ophthalmologic research including age-related macular degeneration, retinistis pigmentosa, and gene expression profiles of RPE.

Lonza now provides these highly specialized cells with optimized growth medium based on proprietary isolation techniques developed by Lonza Walkersville's Research and Development group. Clonetics® HRPE cells are sold at passage 2 and guaranteed through 5 additional population doublings.

Cells are also tested for cell-specific performance in the RtEGM™ Retinal Pigment Epithelial Growth Medium. Performance markers include = 90% positive for pancytokeratin, = 10% positive for fibroblast contamination, = 90% for tight conjunctions, and = 1% positive for endothelial marker CD31.

The retinal pigment epithelium (RPE) is comprised of hexagonal cells organized into a monolayer that is densely packed with pigment granules. RPE cells play a critical role in visual function and photoreceptor viability.